Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.

ABSTRACT:

Background

Thrombosis and inflammation may contribute to morbidity and mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19.

Methods

In an open-label, adaptive, multiplatform, randomized clinical trial, critically ill patients with severe Covid-19 were randomly assigned to a pragmatically defined regimen of either therapeutic-dose anticoagulation with heparin or pharmacologic thromboprophylaxis in accordance with local usual care. The primary outcome was organ support-free days, evaluated on an ordinal scale that combined in-hospital death (assigned a value of -1) and the number of days free of cardiovascular or respiratory organ support up to d

SUBMITTER: REMAP-CAP Investigators 

PROVIDER: S-EPMC8362592 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature